Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.

× No keyword cloud information.

39 in total

1. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.

Authors: Fadi El Karak; Tarek Assi; Hampig Raphael Kourie; Elie El Rassy; Ralph Chebib; Maya Ghor; Samer Tabchi
Journal: Int J Clin Exp Pathol Date: 2015-03-01

Review 2. Lung cancer as a paradigm for precision oncology in solid tumours.

Authors: Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal: Virchows Arch Date: 2017-07-20 Impact factor: 4.064

Review 3. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation.

Authors: Kevin Becker; Yiqing Xu
Journal: World J Clin Oncol Date: 2014-10-10

Review 4. The evidence framework for precision cancer medicine.

Authors: Jeffrey A Moscow; Tito Fojo; Richard L Schilsky
Journal: Nat Rev Clin Oncol Date: 2017-12-19 Impact factor: 66.675

5. Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?

Authors: Darragh F Halpenny; Andrew Plodkowski; Gregory Riely; Junting Zheng; Anya Litvak; Chaya Moscowitz; Michelle S Ginsberg
Journal: Clin Imaging Date: 2016-11-30 Impact factor: 1.605

Review 6. Lung cancer biomarkers, targeted therapies and clinical assays.

Authors: Jai N Patel; Jennifer L Ersek; Edward S Kim
Journal: Transl Lung Cancer Res Date: 2015-10

7. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Authors: Liza C Villaruz; Mark A Socinski; Shira Abberbock; Lynne D Berry; Bruce E Johnson; David J Kwiatkowski; A John Iafrate; Marileila Varella-Garcia; Wilbur A Franklin; D Ross Camidge; Lecia V Sequist; Eric B Haura; Mark Ladanyi; Brenda F Kurland; Kelly Kugler; John D Minna; Paul A Bunn; Mark G Kris
Journal: Cancer Date: 2014-10-01 Impact factor: 6.860

Review 8. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Authors: James E Frampton
Journal: Drugs Date: 2013-12 Impact factor: 9.546

9. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors: Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal: Invest New Drugs Date: 2015-08-20 Impact factor: 3.850

Review 10. Prognostic and predictive biomarkers in lung cancer. A review.

Authors: Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal: Virchows Arch Date: 2014-01-14 Impact factor: 4.064